AYX fell sharply on Q2 financial results that missed estimates and weaker than expected guidance. This article conveys that AYX could be a buying opportunity and a high conviction portfolio holding. A Message From GeoInvesting Arham Khan contributes to GeoInvesting […]
As you may have read recently or noticed, shares of BioXcel Therapeutics (NASDAQ:BTAI) recorded a 627% gain in seven months after SanaCurrents’ December 20, 2019 report that forecast positive outcomes for two, separate phase III trials for BioXcel’s drug BXCL501. The 627% […]